Treatment with immune checkpoint inhibitors (ICI) monotherapy targeting the Programmed cell death – protein/ligand 1 (PD-1/PD-L1) pathway in R/M mucosal head and neck SCC (HNSCC) has demonstrated a benefit over cytotoxic chemotherapy plus cetuximab most pronounced in tumours with higher levels of PD-L1 expression (3). The gene discussed is CD274; the disease is neoplasm.